Merck KGaA reportedly considering generics sale
Free newsletter via e-mail
Tools
Germany's Merck KGaA is mulling the possible sale of its generics drug business, according to a news report. The unit could be worth about €4 billion and the money would help fund its acquisition of Switzerland's Serono as it focuses on developing new therapies. Any sale would likely be to financial investors, analysts note. The European drug company declined to comment on the report.
- here's the AFX report on Merck's plans
Related Articles:
Merck KGaA buying control of Serono. Report
Merck KGaA inks deal with China's Chi-Med. Report
More stories about Drug Development China analysts Serono Generics Darmstadt Germany Switzerland Merck KgAA Mergers and Acquisitions
SHARE
WITH: